Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPAR-gamma agonist pretreatment before peginterferon alfa-2a and ribavirin in previously treatment-resistant hepatitis C
2007-007075-16Phase 4Active
- Sponsor
- VU university medical center
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by VU university medical center. Primary endpoint: Sustained virologic response. Started Jul 2008; status: active.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-007075-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007075-16.